共查询到9条相似文献,搜索用时 2 毫秒
1.
Selective peroxisome proliferator‐activated receptor‐α modulator K‐877 efficiently activates the peroxisome proliferator‐activated receptor‐α pathway and improves lipid metabolism in mice
下载免费PDF全文
![点击此处可从《Journal of diabetes investigation.》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kenta Takei Song‐iee Han Yuki Murayama Aoi Satoh Fusaka Oikawa Hiroshi Ohno Yoshinori Osaki Takashi Matsuzaka Motohiro Sekiya Hitoshi Iwasaki Shigeru Yatoh Naoya Yahagi Hiroaki Suzuki Nobuhiro Yamada Yoshimi Nakagawa Hitoshi Shimano 《Journal of diabetes investigation.》2017,8(4):446-452
2.
3.
4.
5.
6.
Aleglitazar,a dual peroxisome proliferator‐activated receptor‐α/γ agonist,improves insulin sensitivity,glucose control and lipid levels in people with type 2 diabetes: findings from a randomized,double‐blind trial
下载免费PDF全文
![点击此处可从《Diabetes, obesity & metabolism》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A. O. Stirban M. Andjelkovic T. Heise L. Nosek A. Fischer A. Gastaldelli M. Herz 《Diabetes, obesity & metabolism》2016,18(7):711-715
The present single‐centre, randomized, double‐blind, placebo‐controlled phase II study investigated the effect of the balanced dual peroxisome proliferator‐activated receptor‐α/γ agonist aleglitazar on whole‐body and liver insulin sensitivity, β‐cell function and other components of cardiometabolic syndrome after 16 weeks of treatment in patients with type 2 diabetes inadequately controlled with metformin monotherapy who received once‐daily 150 µg aleglitazar or matching placebo as add‐on therapy to metformin. Baseline and 16‐week assessments included a two‐step hyperinsulinaemic–euglycaemic clamp, followed by a hyperglycaemic clamp, as well as evaluation of glycated haemoglobin (HbA1c), lipids and safety variables. The primary endpoint was change in whole‐body insulin sensitivity (M‐value) from baseline compared with placebo, derived from the second clamp step. M‐value improved significantly from baseline with aleglitazar (n = 16) compared with placebo (n = 24; p = 0.05 for difference between arms). We found statistically significant treatment differences with aleglitazar versus placebo in fasting hepatic insulin resistance index (p = 0.01), and in total glucose disposal (p = 0.03) at the second insulin infusion step. Aleglitazar treatment resulted in significant improvements in HbA1c and lipids and was well tolerated. 相似文献
7.
Activation of peroxisome proliferator‐activated receptor‐gamma inhibits tumor growth by negatively regulating nuclear factor‐κB activation in patients with hepatocellular carcinoma
下载免费PDF全文
![点击此处可从《Journal of hepato-biliary-pancreatic sciences》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Hiroyuki Nojima Satoshi Kuboki Kimio Shinoda Hiroaki Shimizu Masayuki Ohtsuka Atsushi Kato Hideyuki Yoshitomi Katsunori Furukawa Tsukasa Takayashiki Masaru Miyazaki 《Journal of hepato-biliary-pancreatic sciences》2016,23(9):574-584
8.
9.
Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high‐fat diet fed mice
下载免费PDF全文
![点击此处可从《Liver international》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Kanji Yamaguchi Takeshi Nishimura Hiroshi Ishiba Yuya Seko Akira Okajima Hideki Fujii Nozomi Tochiki Atsushi Umemura Michihisa Moriguchi Yoshio Sumida Hironori Mitsuyoshi Kohichiroh Yasui Masahito Minami Takeshi Okanoue Yoshito Itoh 《Liver international》2015,35(2):550-561